Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TLSA
TLSA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TLSA News
Biotech Sector Regulatory Approvals and Collaborations
May 22 2026
NASDAQ.COM
Tiziana Life Sciences Completes Patient Enrollment in Foralumab Trial
May 21 2026
stocktwits
Tiziana Completes Enrollment in na-SPMS Clinical Trial
May 21 2026
Newsfilter
Tiziana Releases Positive Clinical Data for Foralumab in MS Treatment
May 20 2026
NASDAQ.COM
Tiziana Life Sciences Reports Positive Data on Foralumab for MS
May 19 2026
seekingalpha
Tiziana Updates Clinical Data Showing Safety and Efficacy of Foralumab
May 19 2026
Newsfilter
Tiziana Life Sciences Publishes Intranasal Foralumab Study, Highlighting Efficacy Potential
Jan 21 2026
NASDAQ.COM
Tiziana Life Sciences Publishes Positive Study Results for Intranasal Foralumab in MS Patients
Jan 20 2026
Newsfilter
Tiziana Life Sciences Closes Direct Offering of 7.04 Million Shares, Raising $8.8 Million
Jan 16 2026
Globenewswire
Tiziana Life Sciences Closes $8.8 Million Direct Offering of 7.04 Million Shares
Jan 16 2026
Newsfilter
Tiziana Life Sciences (TLSA) Completes $8M Direct Offering with Strong Management Participation
Jan 16 2026
seekingalpha
Plus Therapeutics Prices Public Offering, Raising $15 Million
Jan 15 2026
NASDAQ.COM
Tiziana to Present Clinical Progress of Foralumab at Neuroscience Innovation Forum
Jan 09 2026
Globenewswire
Tiziana Submits 37.4 Patient-Years Safety Report for Foralumab, Highlighting Safety Profile
Dec 29 2025
Globenewswire
Tiziana Submits 37.4 Patient-Years Safety Report for Intranasal Foralumab
Dec 29 2025
Newsfilter
Tiziana's Founder Acquires 97,687 Shares, Boosting Holdings to 36.08% of Capital
Dec 19 2025
Globenewswire
Show More News
